Reducing risk
Vaccines, new chemical entities (NCEs), small molecules, biologics, gene therapy. Our experience spans all product types and we understand clinical development in challenging therapy areas. By putting patients first, we reduce the risks of recruitment and retention, and mitigate delays with regulatory authorities.
Working with unique challenges
We’ve encountered many unique challenges that hinder complex hospital-based studies, including rare diseases and oncology trials. But as a full-service CRO of our size, we’re ideally placed to meet them head-on. We maximise site selection, form close links with patient advocacy groups, and enrol patients. We overcome hurdles to help you get medicines to market.